Pharmacology of Stone Disease

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Kidney stone disease remains a major health and economic burden on the nation. It has been increasingly recognized that nephrolithiasis can be both a chronic or systemic illness. There have been major limitations in the development of new drugs for the prevention and management of this disease, largely due to our lack of understanding of the complex pathophysiologic mechanisms involving the interaction of three major target organs: the kidney, bone, and intestine. We also do not yet understand the molecular genetic basis of this polygenic disorder. These limitations are coupled with the incorrect perception that kidney stone disease is solely an acute illness, and the lack of reliable tests to assess outcome measures. All of these factors combined have diminished the willingness of the pharmaceutical industry to engage in the development of novel drugs.

Original languageEnglish (US)
Pages (from-to)30-38
Number of pages9
JournalAdvances in Chronic Kidney Disease
Volume16
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Kidney Calculi
Kidney Diseases
Pharmacology
Nephrolithiasis
Drug Industry
Disease Management
Pharmaceutical Preparations
Intestines
Molecular Biology
Economics
Outcome Assessment (Health Care)
Kidney
Bone and Bones
Health

Keywords

  • Diabetes mellitus
  • Metabolic syndrome
  • Nephrolithiasis
  • Oxalobacter formigines
  • Uric acid
  • Urolithiasisl

ASJC Scopus subject areas

  • Nephrology

Cite this

Pharmacology of Stone Disease. / Sakhaee, Khashayar.

In: Advances in Chronic Kidney Disease, Vol. 16, No. 1, 01.2009, p. 30-38.

Research output: Contribution to journalArticle

@article{80ee56784cc145b4b0d9f22e04ceb789,
title = "Pharmacology of Stone Disease",
abstract = "Kidney stone disease remains a major health and economic burden on the nation. It has been increasingly recognized that nephrolithiasis can be both a chronic or systemic illness. There have been major limitations in the development of new drugs for the prevention and management of this disease, largely due to our lack of understanding of the complex pathophysiologic mechanisms involving the interaction of three major target organs: the kidney, bone, and intestine. We also do not yet understand the molecular genetic basis of this polygenic disorder. These limitations are coupled with the incorrect perception that kidney stone disease is solely an acute illness, and the lack of reliable tests to assess outcome measures. All of these factors combined have diminished the willingness of the pharmaceutical industry to engage in the development of novel drugs.",
keywords = "Diabetes mellitus, Metabolic syndrome, Nephrolithiasis, Oxalobacter formigines, Uric acid, Urolithiasisl",
author = "Khashayar Sakhaee",
year = "2009",
month = "1",
doi = "10.1053/j.ackd.2008.10.004",
language = "English (US)",
volume = "16",
pages = "30--38",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Pharmacology of Stone Disease

AU - Sakhaee, Khashayar

PY - 2009/1

Y1 - 2009/1

N2 - Kidney stone disease remains a major health and economic burden on the nation. It has been increasingly recognized that nephrolithiasis can be both a chronic or systemic illness. There have been major limitations in the development of new drugs for the prevention and management of this disease, largely due to our lack of understanding of the complex pathophysiologic mechanisms involving the interaction of three major target organs: the kidney, bone, and intestine. We also do not yet understand the molecular genetic basis of this polygenic disorder. These limitations are coupled with the incorrect perception that kidney stone disease is solely an acute illness, and the lack of reliable tests to assess outcome measures. All of these factors combined have diminished the willingness of the pharmaceutical industry to engage in the development of novel drugs.

AB - Kidney stone disease remains a major health and economic burden on the nation. It has been increasingly recognized that nephrolithiasis can be both a chronic or systemic illness. There have been major limitations in the development of new drugs for the prevention and management of this disease, largely due to our lack of understanding of the complex pathophysiologic mechanisms involving the interaction of three major target organs: the kidney, bone, and intestine. We also do not yet understand the molecular genetic basis of this polygenic disorder. These limitations are coupled with the incorrect perception that kidney stone disease is solely an acute illness, and the lack of reliable tests to assess outcome measures. All of these factors combined have diminished the willingness of the pharmaceutical industry to engage in the development of novel drugs.

KW - Diabetes mellitus

KW - Metabolic syndrome

KW - Nephrolithiasis

KW - Oxalobacter formigines

KW - Uric acid

KW - Urolithiasisl

UR - http://www.scopus.com/inward/record.url?scp=57449090616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449090616&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2008.10.004

DO - 10.1053/j.ackd.2008.10.004

M3 - Article

C2 - 19095203

AN - SCOPUS:57449090616

VL - 16

SP - 30

EP - 38

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 1

ER -